<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several studies have established an association between iron chelation therapy with <z:chebi fb="0" ids="49005">deferasirox</z:chebi> and hematopoietic improvement in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>There are no data from patients with β-<z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In a cross-sectional study, we evaluated the absolute number of several hematopoietic peripheral progenitors (colony-forming unit-granulocyte/macrophage, erythroid burst-forming units, colony-forming unit-granulocyte/erythrocyte/macrophage/megakaryocyte, and long-term culture-initiating cells) in 30 patients with β-<z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> (median age 29.5 years, 40% males) and 12 age-matched controls </plain></SENT>
<SENT sid="3" pm="."><plain>For the β-<z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> patients, data on splenectomy status, the type of iron <z:chebi fb="0" ids="38161">chelator</z:chebi> used, and serum ferritin levels reflecting changes in iron status on the <z:chebi fb="0" ids="38161">chelator</z:chebi> were also retrieved </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had to be using the same iron <z:chebi fb="0" ids="38161">chelator</z:chebi> for at least 6 months with &gt;80% compliance </plain></SENT>
<SENT sid="5" pm="."><plain>The absolute number of <z:hpo ids='HP_0000001'>all</z:hpo> hematopoietic peripheral progenitors was higher in β-<z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> patients than in controls, and varied between splenectomized and non-splenectomized patients (lower number of erythroid burst-forming units and higher numbers of colony-forming unit-granulocyte/macrophage, colony-forming unit-granulocyte/erythrocyte/macrophage/megakaryocyte, and long-term culture-initiating cells) </plain></SENT>
<SENT sid="6" pm="."><plain>The number of erythroid burst-forming units was significantly higher in patients taking <z:chebi fb="0" ids="49005">deferasirox</z:chebi> (n=10) than in those taking either <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> (n=10) or deferiprone (n=10) (P&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>After adjusting for age, sex, splenectomy status, and serum ferritin changes, the association between a higher absolute number of erythroid burst-forming units in <z:chebi fb="0" ids="49005">deferasirox</z:chebi>-treated patients than in patients taking <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> or deferiprone remained statistically significant (P=0.011) </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, in β-<z:e sem="disease" ids="C0002875" disease_type="Disease or Syndrome" abbrv="">thalassemia major</z:e> patients, compared with other iron <z:chebi fb="0" ids="38161">chelators</z:chebi>, <z:chebi fb="0" ids="49005">deferasirox</z:chebi> therapy is associated with higher levels of circulating erythroid burst-forming units </plain></SENT>
<SENT sid="9" pm="."><plain>This variation is independent of iron status changes and is more likely to be due to the type of <z:chebi fb="0" ids="38161">chelator</z:chebi> </plain></SENT>
</text></document>